The market for the CCR5 antagonist is enormous, lo

The market for the CCR5 antagonist is enormous, logically that there will be more of them going to that direction. I can freely say that CYDY has no financial, human, and technical capabilities to cover it all. We need a partnership with BP, the NP said that the BP came back to the table and talked. In the same interview, the NP said they did not want anyone to give exclusivity to Leronlimab because it has a role in so much disease. The NP said that we have the possibility of partnership with more companies and he apparently wants to go so that no one has to give exclusivity to Leronlimab. But BP apparently wants exclusivity for all the diseases that Leronlimab can potentially treat and there is a major problem. The NP probably wants to partner with BP for HIV-1 indications but does not want it to include cancer and other indications, BP want exclusivity. Further on, the NP said in the last video that the idea of ​​the TO has opponents in CYDY and outside CYDY. Who would be an opponent TO outside of CYDY I do not know. I guess the opponents in CYDY were those who advocated the idea of ​​a durable financing solution by partnering with BP or some other way and that TO was again temporarily resolved by the end of the year. The NP said that big banks tell him to go without Gilead, probably his plan to go to TO by the end of the year, clean up as many warrants, get a partnership without BP, and then get funds into CYDY and big banks.
There are all good options that will speed things up and that funding does not slow down science. The NP said that in CC for a week or two would explain the solution that such delays are no longer happening, I'm looking forward to every solution. Next year we will have two sources of income, combo and Prostate prognostic cancer test, but we must ensure that science and trials can progress without restriction until then.